Pierre Fabre and H-Immune Announce Strategic Research Partnership to Develop Potentially Ground-Breaking Cancer Immunotherapies
Pierre Fabre, the second largest privately held pharmaceutical company in France, and H-Immune SAS, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, today announced that they have entered into a strategic research partnership which will utilize H-Immune’s unique technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170321005742/en/
As a newly established bioscience company in the immuno-oncology field and spin out from the French Atomic Energy Commission, H-Immune has developed a proprietary In Vitro Immunization (IVI) technology leveraging a breakthrough approach to generate a series of fully human monoclonal antibodies (mAbs) against any therapeutic target, taking advantage of the affinity maturation processes performed in situ by B lymphocytes.
“Pierre Fabre is an ideal partner for H-Immune to help us begin to realize the full potential of our science and IVI technology which we plan to exploit through multiple industry partnerships,” said Luc Boblet, PhD, Co-Founder and CEO of H-Immune. “This collaboration is designed to catalyze and create tremendous ongoing scientific and product development synergy by leveraging each company’s strengths and assets.”
Under the terms of the agreement, Pierre Fabre will have access to H-Immune’s IVI technology for three different discovery programs in the field of immuno-oncology.
“This transaction strengthens Pierre Fabre’s position in the areas of immuno-oncology and novel cutting-edge biotherapeutics,” said Laurent Audoly, Head of R&D of Pierre Fabre Pharmaceuticals. “H-Immune is developing an antibody technology platform that we are looking forward to accessing as part of our ongoing efforts to identify and develop world-class novel cancer therapeutics. We believe this collaboration enhances the potential of both partners to deliver transformational therapies to patients in areas of significant unmet medical needs.”
Pierre Fabre has a longstanding commitment to development of pharmaceuticals through its Pierre Fabre Immunology Centre of excellence (CIPF) based in Saint-Julien-en-Genevois, France, which is dedicated to the identification, development and manufacturing of biologics.
The financial terms of the agreement, which include expertise contribution, R&D funding, and milestone payments to H-Immune, were not disclosed.
To find out more about Pierre Fabre, please go to www.pierre-fabre.com.
To find out more about H-Immune, please go to www.h-immune.com.
Pierre Fabre Pharmaceuticals, Castres, France
PHONE: +33 1 49 10 83 84
Deputy Director of Media Relations -- Medicine and Health
H-Immune, Paris, France
Luc Boblet, PhD
PHONE: +33 6 49 17 45 11
Chief Executive Officer
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Advantis Medical Imaging Receives CE Mark for Brainance® MD, its Cloud-Based Neuroimaging Software.20.3.2018 11:00 | Pressemelding
Advantis Medical Imaging announces that it received CE Mark approval for Brainance ® MD, its Cloud-Based Neuroimaging software. This market approval allows Brainance ® MD to be used as part of the clinical workflow for the advanced processing of Brain MR images. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005408/en/ “We feel really excited to make this announcement. This is a significant milestone for our company and the fact that Brainance ® MD can now be integrated in the clinical processing workflow fulfills one of Advantis principal goals: to make state-of-the-art processing methodologies available for every doctor, anywhere, anytime. ” said Zoi Giavri, CEO and co-founder of Advantis Medical Imaging. “This CE Mark approval confirms our capacity for innovation and justifies the entire team’s devotion and effort on striving for increased quality and performance, while bringing added value to the daily clinical pra
Tan Delta: Not All Condition Based Monitoring is the Same.20.3.2018 10:35 | Pressemelding
Condition based monitoring (CBM) and maintenance programmes typically include many interrelated technologies. CBM provides an assessment of equipment condition, based on collecting and interpreting data with a view to providing maintenance at the optimum point. This allows a company to make cost-effective and logical maintenance decisions, reducing scheduled costs and reducing in-service fault repair costs, by eliminating run-to-failure and the associated consequences of unscheduled downtime. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005681/en/ Tan Delta: Not All Condition Based Monitoring is the Same. (Photo: Business Wire) Oil analysis is increasingly recognised as a critical element of condition based monitoring. Oil analysis provides important information about equipment wear-condition, as well as the condition of the oil itself. Keeping machinery operating at the optimal level involves measuring, monitoring a
Accudyne Industries Selects LTI as its IT Infrastructure & Security Management Partner20.3.2018 10:30 | Pressemelding
Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company, has been selected by Accudyne Industries, LLC (Accudyne Industries) as the transformation partner to provide IT Infrastructure & Security Management Services. Accudyne Industries is a leading global provider of precision engineered, process-critical and technologically advanced flow control systems and industrial compressors. Accudyne’s businesses support complex, large-scale installations within oil and gas, energy, petrochemical, chemical, industrial manufacturing, construction, mining, and water and wastewater treatment industries. Accudyne chose LTI as its consulting and IT services partner to enhance end-user experience while attaining flexibility and scalability across its business landscape. LTI will provide services leveraging an intelligent, global, managed services engagement model supported by a command and security operations center. Frank DeArmas, Chief Info
Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis20.3.2018 10:09 | Pressemelding
New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005661/en/ “Long-term, ‘real-world’ data are i
IDEMIA: Easier Travel with the Biometric Innovations Presented at Passenger Terminal Expo (20–22 March 2018)20.3.2018 09:46 | Pressemelding
IDEMIA, the global leader in Augmented Identity, has announced his attendance to Passenger Terminal Expo (PTE) 2018, the world’s biggest aviation industry exhibition. Bringing together all industry stakeholders, including airlines, airport operators and public authorities, PTE begins today and will be held in Stockholm until March 22 nd . As passenger numbers in airports continue to soar1, the need to manage flows efficiently coupled with particularly rigorous screening procedures, is becoming more strategic than ever. With its innovative Augmented Identity, IDEMIA provides a smoother passenger experience based on identification whilst ensuring that security requirements are respected. In that context, IDEMIA today operates free-flow passenger solutions in several international airports through the world. For instance, Singapore Changi Airport, voted the world’s best airport for the fifth consecutive year, recently chose IDEMIA for the provision of biometric identification and authenti
ESSENZIALED Recessed & Linear Lamps Have Adopted Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs20.3.2018 08:07 | Pressemelding
Seoul Semiconductor, a global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs, which implement light closest to the spectrum of natural sunlight, has been adopted for luminaires from ESSENZIALED, including the Spottone and Mood Series luminaires. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005246/en/ ESSENZIALED Mood-Round & Square spotlights with SunLike LEDs (Photo: Business Wire) Marino Bertazza, CEO and founder of ESSENZIALED, explained, “SunLike technology delivers a superior color rendering index, with a spectrum that closely matches that of natural sunlight. Our customers appreciate the quality of light and the visual comfort delivered by SunLike Series natural spectrum LEDs.” According to Caleb Won, executive VP of global marketing at Seoul Semiconductor, “ESSENZIALED’s choice of SunLike Series natural spectrum LEDs will achieve synergy effects and contribute